Publications & Presentations


August 2018 | ARQ 531 / Pre-clinical
The BTK Inhibitor ARQ 531 Targets Ibrutinib Resistant CLL and Richter’s Transformation
Cancer Discovery
Presented by: J. Woyach, S. Reiff, et. al.

June 2018 | ARQ 531 / Clinical
A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies
23nd Congress of the European Hematology Association (EHA)
Presented by: J. Woyach, et al.

April 2018 | ARQ 092 / Oncology
A phase 1b study of miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER+ endometrial and ovarian cancer
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: V. Makker, et al.

April 2018 | ARQ 751
Results of A Phase 1 Dose Escalation Study of ARQ 751 in Adult Subjects with Advanced Solid Tumors with AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or Other Known Actionable PTEN Mutations
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: S. Pant, et al.

April 2018 | ARQ 092 / Pre-clinical
Combinations of Imatinib Mesylate with AKT inhibitor (miransertib, ARQ 751) or FGFR inhibitor (derazantinib) show synergy in GIST cell lines and pre-clinical models
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: M. Kozinova, et al.

April 2018 | ARQ 531 / Pre-clinical
In Vitro and In Vivo Effect of ARQ 531 on Trk Family Kinases
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: Y. Yu, et al.

April 2018 | ARQ 531 / Pre-clinical
ARQ 531, a Reversible BTK Inhibitor, Exhibits Potent Anti-tumor Activity in Ibrutinib-Resistant Diffuse Large B-cell Lymphoma
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: S. Eathiraj, et al.

April 2018 | ARQ 531 / Clinical
ARQ 531, a Novel and Reversible Inhibitor of Bruton’s Tyrosine Kinase, Displays Favorable Oral Bioavailability and Exposure in Patients with B-cell Malignancies
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: T. Hall, et al.

April 2018 | ARQ 531 / Pre-clinical,  ARQ 092 / Pre-clinical
In Vitro and In Vivo Combination of Miransertib (ARQ 092) with Anti-PD-1 Antibody, Trametinib, Lapatinib, Trastuzumab, Paclitaxel and ARQ 531
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: Y. Yu, et al.

April 2018 | ARQ 087 / iCCA
Derazantinib (ARQ 087) Pharmacodynamics: Alterations in FGF19/21/23 and Phosphate in Patients with Cholangiocarcinoma
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: T. Hall, et al.

March 2018 | ARQ 092 / Pre-clinical
In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
neurogenetics
Presented by: C. Ranieri, et al.

January 2018 | ARQ 092 / Pre-clinical
Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
Oncotarget
Presented by: Z. Jilkova, et al.

December 2017 | ARQ 092 / Pre-clinical
Dual Inhibition of AKT and KIT is synergistic in Gastrointestinal Stromal Tumor
CTOS 2017 Annual Meeting
Presented by: M. Kozinova, et. al.

October 2017 | ARQ 087 / iCCA
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.
British Journal of Cancer (BJC)
Presented by: KP. Papadopoulos, et al.

July 2017 | ARQ 092 / Rare Disease
Quantifying survival in patients with Proteus syndrome
Genetics in Medicine
Presented by: J. Sapp, et al.

June 2017 | ARQ 531 / Pre-clinical
ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity in ABC-DLBCL and GCB-DLBCL
2017 European Hematology Association (EHA)
Presented by: S. Eathiraj, et al.

June 2017 | ARQ 092 / Pre-clinical
In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines associated hypertrophic cardiomyopathy
PLOS One
Presented by: J. Wang, et al.

June 2017 | ARQ 092 / Pre-clinical
Results of a Phase 1b Study of ARQ 092 in Combination with Carboplatin (C) Plus Paclitaxel (P) or with Paclitaxel in Patients with Solid Tumors
2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Presented by: N. Lakhani, et al.

June 2017 | ARQ 761
Phase 1 Study of ARQ 761, a ß-lapachone analog that promotes NQO1-mediated programmed cancer cell
2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Presented by: D. Gerber, et al.

June 2017 | ARQ 092 / Pre-clinical
Efficacy of AKT inhibitor ARQ 092 compared with sorafenib in a cirrhotic rat model with hepatocellular carcinoma
Molecular Cancer Therapeutics
Presented by: G. Roth, et al.

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300